Gemcitabine potentiates the anti-tumour effect of radiation on medullary thyroid cancer

Abstract

Patients with medullary thyroid cancer (MTC) are often diagnosed with spread tumour disease and the development of better systemic treatment options for these patients is important. Treatment with the radiolabelled somatostatin analogue 177Lu-octreotate is already a promising option but can be optimised. For example, combination treatment with another substance could increase the effect on tumour tissue. Gemcitabine is a nucleoside analogue that has been shown to sensitise tumour cells to radiation. The aim of this study was to investigate potentially additive or synergistic effects of combining radiation with gemcitabine for treatment of MTC. Nude mice transplanted with patient-derived MTC tumours (GOT2) were divided into groups and treated with radiation and/or gemcitabine. Radiation treatment was given as 177Lu-octreotate or external beam radiotherapy (EBRT). The volume of treated and untreated tumours was followed. The absorbed dose and amount of gemcitabine were chosen to give moderate tumour volume reduction when given as monotherapy to enable detection of increased effects from combination treatment. After follow-up, the mice were killed and tumours were immunohistochemically (IHC) analysed. Overall, the animals that received a combination of EBRT and gemcitabine showed the largest reduction in tumour volume. Monotherapy with EBRT or gemcitabine also resulted in a clear detrimental effect on tumour volume, while the animals that received 177Lu-octreotate monotherapy showed similar response as the untreated animals. The GOT2 tumour was confirmed in the IHC analyses by markers for MTC. The IHC analyses also revealed that the proliferative activity of tumour cells was similar in all tumours, but indicated that fibrotic tissue was more common after EBRT and/or gemcitabine treatment. The results indicate that an additive, or even synergistic, effect may be achieved by combining radiation with gemcitabine for treatment of MTC. Future studies should be performed to evaluate the full potential of combining 177Lu-octreotate with gemcitabine in patients.

Gemcitabine–Ibandronate Conjugate Enables the Bone-Targeted Combination Therapy in Bone Cancer: Synthesis and Efficacy in Combination with Docetaxel

“…The GEM–IB level, DTX level, and molar equivalents of GEM and IB used here were markedly lower than the GEM − and DTX , levels in other published mouse xenograft studies. The clinically used doses of GEM and DTX are 1000 mg/m 2 = 27 mg/kg (days 1 and 8 of a 21 day cycle) and 75 mg/m 2 = 2 mg/kg (once every 3 weeks), respectively.…”

Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors

“…Therefore, it is likely that the anti-tumour effects seen here could be significantly increased by higher treatment doses. The absorbed dose from EBRT was determined based on previous data in our research group, where 5 Gy delivered to GOT2 tumours resulted in an RTV of 0.57 at about two weeks after treatment [37]. The absorbed dose of 3 Gy used in this study instead resulted in a corresponding RTV of about 0.9, which was similar to the effect from TKI monotherapy (RTV�1.0).…”

SapC–DOPS as a Novel Therapeutic and Diagnostic Agent for Glioblastoma Therapy and Detection: Alternative to Old Drugs and Agents

“…A number of identified chemotherapeutic agents have been used as radiosensitizers, and they have favorably improved the efficacy of radiotherapy for various cancers in clinical trials [59]. For instance, gemcitabine is also an efficient radiosensitizer in the treatment of many cancers, such as thyroid cancer, pancreatic cancer, and sarcoma [60][61][62]. While many chemotherapeutic agents have been investigated as potential radiosensitizers for GBM, most have failed in clinical trials.…”